Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by WORKINMONTANAon Mar 29, 2019 6:27pm

196 Views

Post# 29556821

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:What is the volatility going to fluctuat to?

There are now five studies listed listed in regards to ongoing trials. Have a look

WORKINMONTANA wrote: If you diagnose the LINK I included you can clearly see that phase 3 is already listed for Acute I & II

Were you and your family members sent out down the drop gate first during D-Day, sincere condolences Sir/Madamme

WORKINMONTANA wrote: @eqwitty if you can not do something properly just ask, geeze mate.

LINK > https://clinicaltrials.gov/ct2/results?

eqwitty wrote: What's very concerning is that their phase 2B prevention is not even listed on clinicaltrials.gov...every compay that is seeking FDA must list their trial on this site.